IDX signs Cleveland Clinic as partner for new offeringIDX Systems has announced that the Cleveland Clinic will install the HIS vendor's Enterprise Radiology Image and Information Management System, which provides enterprise-wide access to
IDX Systems has announced that the Cleveland Clinic will install the HIS vendor's Enterprise Radiology Image and Information Management System, which provides enterprise-wide access to radiology images and information (
PNN
11/97). The Cleveland Clinic, which already owns the firm's IDXrad RIS, will install the Enterprise Radiology Image and Information Management System at all of its facilities in Ohio and Indiana.
IDX's new offering features relational and Web-based architecture that automates radiology department processes and offers customers the ability to design site-specific work-flow processes and to provide load balancing of staff and resources, according to the Burlington, VT-based company.
In other IDX news, the vendor has joined the Oracle Alliance, which allows the company to employ the database firm's server technology. The company expects to migrate IDXrad to the Oracle SQL platform.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.